Browse the corpus

REFERENCES AuBuchon JP, Birkmeyer JD, Busch MP. Safety of the blood supply in the United States: opportunities and controversies. Ann Intern Med 1997; 127:904. Stramer SL, Caglioti S, Strong DM. NAT of the United States and Canadian blood supply. Transfusion 2000; 40:1165. Dodd RY, Notari EP 4th, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion 2002; 42:975. Zou S, Dorsey KA, Notari EP, et al. Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing. Transfusion 2010; 50:1495. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med 1996; 334:1685. Zou S, Stramer SL, Notari EP, et al. Current incidence and residual risk of hepatitis B infection among blood donors in the United States. Transfusion 2009; 49:1609. Donegan E, Lee H, Operskalski EA, et al. Transfusion transmission of retroviruses: human T-lymphotropic virus types I and II compared with human immunodeficiency virus type 1. Transfusion 1994; 34:478. Kleinman S. Donor screening procedures. In: Clinical Practice of Transfusion Medicine, 3rd ed, Petz L, Swisher S, Kleinman S, et al (Eds), Churchill-Livingstone, New York 1996. p.245. Glynn SA, Kleinman SH, Schreiber GB, et al. Trends in incidence and prevalence of major transfusion-transmissible viral infections in US blood donors, 1991 to 1996. Retrovirus Epidemiology Donor Study (REDS). JAMA 2000; 284:229. Zou S, Notari EP 4th, Stramer SL, et al. Patterns of age- and sex-specific prevalence of major blood-borne infections in United States blood donors, 1995 to 2002: American Red Cross blood donor study. Transfusion 2004; 44:1640. O'Brien SF, Fan W, Xi G, et al. Declining hepatitis C rates in first-time blood donors: insight from surveillance and case-control risk factor studies. Transfusion 2008; 48:902. FDA Guidance for Industry: Acceptable full-length donor history questionnaire and accompanying materials for use in screening human donors of blood and blood components. file://www.fda.gov/cber//blood/bldguid.htm (Accessed on October 06, 2011).

O'Brien SF, Fan W, Xi G, et al. Declining hepatitis C rates in first-time blood donors: insight from surveillance and case-control risk factor studies. Transfusion 2008; 48:902. FDA Guidance for Industry: Acceptable full-length donor history questionnaire and accompanying materials for use in screening human donors of blood and blood components. file://www.fda.gov/cber//blood/bldguid.htm (Accessed on October 06, 2011). Katz LM, Cumming PD, Wallace EL, Abrams PS. Audiovisual touch-screen computer-assisted self-interviewing for donor health histories: results from two years experience with the system. Transfusion 2005; 45:171. Center for Biologics Evaluation and Research, Food and Drug Administration. Guidance for Industry: Recommendations for deferral of donors and quarantine and retrieval of blood and blood products in recent recipients of smallpox vaccine (vaccinia virus) and certain contacts of smallpox vaccine recipients. December 2002. Centers for Disease Control and Prevention (CDC). Transfusion-related transmission of yellow fever vaccine virus--California, 2009. MMWR Morb Mortal Wkly Rep 2010; 59:34. Director, Center for Biologics Evaluation and Research: Recommendations for the prevention of human immunodeficiency virus (HIV) transmission by blood and blood products. Memorandum to all registered blood establishments. April 23, 1992. Director, Center for Biologics Evaluation and Research, Food and Drug Administration: Recommendations for the deferral of current and recent inmates of correctional institutions as donors of whole blood, blood components, source leukocytes, and source plasma. Memorandum to all registered blood establishments. June 8, 1995. Director, Center for Biologics Evaluation and Research, Food and Drug Administration: Interim recommendations for deferral of donors at increased risk for HIV-1 group O infection. Memorandum to all registered blood and plasma establishments. December 11, 1996. Sheppard HW, Dondero D, Arnon J, Winkelstein W Jr. An evaluation of the polymerase chain reaction in HIV-1 seronegative men. J Acquir Immune Defic Syndr 1991; 4:819. Jackson JB. Human immunodeficiency virus (HIV)-indeterminate western blots and latent HIV infection. Transfusion 1992; 32:497. Busch MP, Satten GA. Time course of viremia and antibody seroconversion following human immunodeficiency virus exposure. Am J Med 1997; 102:117.

Sheppard HW, Dondero D, Arnon J, Winkelstein W Jr. An evaluation of the polymerase chain reaction in HIV-1 seronegative men. J Acquir Immune Defic Syndr 1991; 4:819. Jackson JB. Human immunodeficiency virus (HIV)-indeterminate western blots and latent HIV infection. Transfusion 1992; 32:497. Busch MP, Satten GA. Time course of viremia and antibody seroconversion following human immunodeficiency virus exposure. Am J Med 1997; 102:117. Ridzon R, Gallagher K, Ciesielski C, et al. Simultaneous transmission of human immunodeficiency virus and hepatitis C virus from a needle-stick injury. N Engl J Med 1997; 336:919. Lindbäck S, Thorstensson R, Karlsson AC, et al. Diagnosis of primary HIV-1 infection and duration of follow-up after HIV exposure. Karolinska Institute Primary HIV Infection Study Group. AIDS 2000; 14:2333. Germain M, Remis RS, Delage G. The risks and benefits of accepting men who have had sex with men as blood donors. Transfusion 2003; 43:25. Soldan K, Sinka K. Evaluation of the de-selection of men who have had sex with men from blood donation in England. Vox Sang 2003; 84:265. Anderson SA, Yang H, Gallagher LM, et al. Quantitative estimate of the risks and benefits of possible alternative blood donor deferral strategies for men who have had sex with men. Transfusion 2009; 49:1102. Available on the United States FDA website at: file://www.fda.gov/cber/faq/msmdonor.htm (Accessed on May 24, 2007). Seed CR, Kiely P, Law M, Keller AJ. No evidence of a significantly increased risk of transfusion-transmitted human immunodeficiency virus infection in Australia subsequent to implementing a 12-month deferral for men who have had sex with men. Transfusion 2010; 50:2722. Hurley R. UK lifts lifetime ban on gay men giving blood. BMJ 2011; 343:d5765. Williams AE, Thomson RA, Schreiber GB, et al. Estimates of infectious disease risk factors in US blood donors. Retrovirus Epidemiology Donor Study. JAMA 1997; 277:967. Glynn SA, Smith JW, Schreiber GB, et al. Repeat whole-blood and plateletpheresis donors:unreported deferrable risks, reactive screening tests, andresponse to incentive programs. Transfusion 2001; 41:736. Maclennan S, Barbara JA, Hewitt P, et al. Screening blood donations for HCV. Lancet 1992; 339:131.

Williams AE, Thomson RA, Schreiber GB, et al. Estimates of infectious disease risk factors in US blood donors. Retrovirus Epidemiology Donor Study. JAMA 1997; 277:967. Glynn SA, Smith JW, Schreiber GB, et al. Repeat whole-blood and plateletpheresis donors:unreported deferrable risks, reactive screening tests, andresponse to incentive programs. Transfusion 2001; 41:736. Maclennan S, Barbara JA, Hewitt P, et al. Screening blood donations for HCV. Lancet 1992; 339:131. Doll LS, Petersen LR, White CR, Ward JW. Human immunodeficiency virus type 1-infected blood donors: behavioral characteristics and reasons for donation. The HIV Blood Donor Study Group. Transfusion 1991; 31:704. Centers for Disease Control and Prevention (CDC). HIV transmission through transfusion --- Missouri and Colorado, 2008. MMWR Morb Mortal Wkly Rep 2010; 59:1335. Orton SL, Virvos VJ, Williams AE. Validation of selected donor-screening questions: structure, content, and comprehension. Transfusion 2000; 40:1407. US Department of Health and Human Services, Food and Drug Administration. The code of federal regulations, US Government Printing Office, Washington, DC, 1997; (Revised annually). Director, Center for Biologics Evaluation and Research, Food and Drug Administration: Donor suitability related to laboratory testing for viral hepatitis and a history of viral hepatitis. Memorandum to all registered blood establishments. December 22, 1993. Sherertz RJ, Russell BA, Reuman PD. Transmission of hepatitis A by transfusion of blood products. Arch Intern Med 1984; 144:1579. Goldman M, Xi G, Yi QL, et al. Reassessment of deferrals for tattooing and piercing. Transfusion 2009; 49:648. Perrillo RP, Gelb L, Campbell C, et al. Hepatitis B e antigen, DNA polymerase activity, and infection of household contacts with hepatitis B virus. Gastroenterology 1979; 76:1319. Alter MJ. The detection, transmission, and outcome of hepatitis C virus infection. Infect Agents Dis 1993; 2:155. Guerrero IC, Weniger BG, Schultz MG. Transfusion malaria in the United States, 1972-1981. Ann Intern Med 1983; 99:221. Nahlen BL, Lobel HO, Cannon SE, Campbell CC. Reassessment of blood donor selection criteria for United States travelers to malarious areas. Transfusion 1991; 31:798. Mungai M, Tegtmeier G, Chamberland M, Parise M. Transfusion-transmitted malaria in the United States from 1963 through 1999. N Engl J Med 2001; 344:1973.

Guerrero IC, Weniger BG, Schultz MG. Transfusion malaria in the United States, 1972-1981. Ann Intern Med 1983; 99:221. Nahlen BL, Lobel HO, Cannon SE, Campbell CC. Reassessment of blood donor selection criteria for United States travelers to malarious areas. Transfusion 1991; 31:798. Mungai M, Tegtmeier G, Chamberland M, Parise M. Transfusion-transmitted malaria in the United States from 1963 through 1999. N Engl J Med 2001; 344:1973. Director, Center for Biologics Evaluation and Research, Food and Drug Administration: Recommendations for deferral of donors for malaria risk. Memorandum to all registered blood establishments. July 26, 1994. Spencer B, Steele W, Custer B, et al. Risk for malaria in United States donors deferred for travel to malaria-endemic areas. Transfusion 2009; 49:2335. Center for Biologics Evaluation and Research, Food and Drug Administration: Guidance for Industry. Recommendations for donor questioning regarding possible exposure to malaria. June 2000. Schmunis GA. Prevention of transfusional Trypanosoma cruzi infection in Latin America. Mem Inst Oswaldo Cruz 1999; 94 Suppl 1:93. Leiby DA. Babesiosis and blood transfusion: flying under the radar. Vox Sang 2006; 90:157. Herwaldt BL, Linden JV, Bosserman E, et al. Transfusion-associated babesiosis in the United States: a description of cases. Ann Intern Med 2011; 155:509. Appleman MD, Shulman IA, Saxena S, Kirchhoff LV. Use of a questionnaire to identify potential blood donors at risk for infection with Trypanosoma cruzi. Transfusion 1993; 33:61. Gerber MA, Shapiro ED, Krause PJ, et al. The risk of acquiring Lyme disease or babesiosis from a blood transfusion. J Infect Dis 1994; 170:231. O'Brien SF, Chiavetta JA, Fan W, et al. Assessment of a travel question to identify donors with risk of Trypanosoma cruzi: operational validity and field testing. Transfusion 2008; 48:755. Piron M, Vergés M, Muñoz J, et al. Seroprevalence of Trypanosoma cruzi infection in at-risk blood donors in Catalonia (Spain). Transfusion 2008; 48:1862. Kirchhoff LV, Paredes P, Lomelí-Guerrero A, et al. Transfusion-associated Chagas disease (American trypanosomiasis) in Mexico: implications for transfusion medicine in the United States. Transfusion 2006; 46:298. Guzmán Bracho C, García García L, Floriani Verdugo J, et al. [Risk of transmission of Trypanosoma cruzi by blood transfusion in Mexico]. Rev Panam Salud Publica 1998; 4:94.

Kirchhoff LV, Paredes P, Lomelí-Guerrero A, et al. Transfusion-associated Chagas disease (American trypanosomiasis) in Mexico: implications for transfusion medicine in the United States. Transfusion 2006; 46:298. Guzmán Bracho C, García García L, Floriani Verdugo J, et al. [Risk of transmission of Trypanosoma cruzi by blood transfusion in Mexico]. Rev Panam Salud Publica 1998; 4:94. Leiby DA, Herron RM Jr, Read EJ, et al. Trypanosoma cruzi in Los Angeles and Miami blood donors: impact of evolving donor demographics on seroprevalence and implications for transfusion transmission. Transfusion 2002; 42:549. Stramer SL, Foster GA, Herron RM, et al. US blood donor screening for Trypanasoma cruzi: Clinical studies and early assessment of prevalence (abstract). Transfusion 2007; 47:1A. Tobler LH, Contestable P, Pitina L, et al. Evaluation of a new enzyme-linked immunosorbent assay for detection of Chagas antibody in US blood donors. Transfusion 2007; 47:90. Stramer SL, Foster G, Townsend R, et al. Trypanasoma Cruzi antibody screening in US blood donors: one year experience at the American Red Cross (abstract). Transfusion 2008; 48:(Suppl)2A. Dodd RY, Lipton KS. Deferral for risk of leishmaniasis exposure. October 10, 2003. Letter available on the American Association of Blood Banks website at: www.aabb.org (Accessed on October 10, 2003). Centers for Disease Control and Prevention (CDC). Cutaneous leishmaniasis in U.S. military personnel--Southwest/Central Asia, 2002-2003. MMWR Morb Mortal Wkly Rep 2003; 52:1009. Mestra L, Lopez L, Robledo SM, et al. Transfusion-transmitted visceral leishmaniasis caused by Leishmania (Leishmania) mexicana in an immunocompromised patient: a case report. Transfusion 2011; 51:1919. AABB. Association Bulletin #03-14. Deferral for risk of Leishmaniasis exposure. October 10, 2003 www.aabb.org; members only section (Accessed on October 10, 2003). Cardo LJ. Leishmania: risk to the blood supply. Transfusion 2006; 46:1641. Ricketts MN, Cashman NR, Stratton EE, ElSaadany S. Is Creutzfeldt-Jakob disease transmitted in blood? Emerg Infect Dis 1997; 3:155. Brown P. Can Creutzfeldt-Jakob disease be transmitted by transfusion? Curr Opin Hematol 1995; 2:472. Holman RC, Khan AS, Belay ED, Schonberger LB. Creutzfeldt-Jakob disease in the United States, 1979-1994: using national mortality data to assess the possible occurrence of variant cases. Emerg Infect Dis 1996; 2:333.

Ricketts MN, Cashman NR, Stratton EE, ElSaadany S. Is Creutzfeldt-Jakob disease transmitted in blood? Emerg Infect Dis 1997; 3:155. Brown P. Can Creutzfeldt-Jakob disease be transmitted by transfusion? Curr Opin Hematol 1995; 2:472. Holman RC, Khan AS, Belay ED, Schonberger LB. Creutzfeldt-Jakob disease in the United States, 1979-1994: using national mortality data to assess the possible occurrence of variant cases. Emerg Infect Dis 1996; 2:333. Evatt B, Austin H, Barnhart E, et al. Surveillance for Creutzfeldt-Jakob disease among persons with hemophilia. Transfusion 1998; 38:817. Dodd RY, Sullivan MT. Creutzfeldt-Jakob disease and transfusion safety: tilting at icebergs? Transfusion 1998; 38:221. Will RG, Ironside JW, Zeidler M, et al. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 1996; 347:921. UK government Department of Health Web site on CJD/BSE. www.doh.gov.uk/cjd (Accessed on March 08, 2005). Hill AF, Desbruslais M, Joiner S, et al. The same prion strain causes vCJD and BSE. Nature 1997; 389:448. Murphy MF. New variant Creutzfeldt-Jakob disease (nvCJD): the risk of transmission by blood transfusion and the potential benefit of leukocyte-reduction of blood components. Transfus Med Rev 1999; 13:75. Hill AF, Butterworth RJ, Joiner S, et al. Investigation of variant Creutzfeldt-Jakob disease and other human prion diseases with tonsil biopsy samples. Lancet 1999; 353:183. Burthem J, Roberts DJ. The pathophysiology of variant Creutzfeldt-Jacob disease: the hypotheses behind concerns for blood components and products. Br J Haematol 2003; 122:3. Houston F, Foster JD, Chong A, et al. Transmission of BSE by blood transfusion in sheep. Lancet 2000; 356:999. Houston F, McCutcheon S, Goldmann W, et al. Prion diseases are efficiently transmitted by blood transfusion in sheep. Blood 2008; 112:4739. Hewitt PE, Llewelyn CA, Mackenzie J, Will RG. Creutzfeldt-Jakob disease and blood transfusion: results of the UK Transfusion Medicine Epidemiological Review study. Vox Sang 2006; 91:221. Lefrère JJ, Hewitt P. From mad cows to sensible blood transfusion: the risk of prion transmission by labile blood components in the United Kingdom and in France. Transfusion 2009; 49:797. Llewelyn CA, Hewitt PE, Knight RS, et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 2004; 363:417.

Lefrère JJ, Hewitt P. From mad cows to sensible blood transfusion: the risk of prion transmission by labile blood components in the United Kingdom and in France. Transfusion 2009; 49:797. Llewelyn CA, Hewitt PE, Knight RS, et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 2004; 363:417. Peden AH, Head MW, Ritchie DL, et al. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 2004; 364:527. Wilson K, Ricketts MN. The success of precaution? Managing the risk of transfusion transmission of variant Creutzfeldt-Jakob disease. Transfusion 2004; 44:1475. Murphy EL, David Connor J, McEvoy P, et al. Estimating blood donor loss due to the variant CJD travel deferral. Transfusion 2004; 44:645. Millar CM, Makris M. Dealing with the uncertain risk of variant Creutzfeldt-Jakob disease transmission by coagulation replacement products. Br J Haematol 2012; 158:442. Dietz K, Raddatz G, Wallis J, et al. Blood transfusion and spread of variant Creutzfeldt-Jakob disease. Emerg Infect Dis 2007; 13:89. FDA Guidance for Industry: Revised recommendations for the assessment of donor suitability and blood and blood product safety in cases of known or suspected West Nile virus infection. May 2003. file://www.fda.gov/cber/guidelines.htm (Accessed on May 01, 2003). Orton SL, Stramer SL, Dodd RY. Self-reported symptoms associated with West Nile virus infection in RNA-positive blood donors. Transfusion 2006; 46:272. Richards C, Kolins J, Trindade CD. Autologous transfusion-transmitted Yersinia enterocolitica. JAMA 1992; 268:154. Vargas SO, Cannon ME, Benjamin RJ, Longtine JA. Transfusion with blood from a donor with chronic myelogenous leukemia: persistence of the bcr/abl translocation in the recipient. Transfusion 1999; 39:387. Edgren G, Hjalgrim H, Reilly M, et al. Risk of cancer after blood transfusion from donors with subclinical cancer: a retrospective cohort study. Lancet 2007; 369:1724. Greenwald P, Woodard E, Nasca PC, et al. Morbidity and mortality among recipients of blood from preleukemic and prelymphomatous donors. Cancer 1976; 38:324. Acting Director, Office of Blood Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration: Deferral of blood and plasma donors based on medications. Memorandum to all registered blood establishments. July 28, 1993.

Greenwald P, Woodard E, Nasca PC, et al. Morbidity and mortality among recipients of blood from preleukemic and prelymphomatous donors. Cancer 1976; 38:324. Acting Director, Office of Blood Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration: Deferral of blood and plasma donors based on medications. Memorandum to all registered blood establishments. July 28, 1993. Food and Drug Administration. Guidance for industry and FDA review staff: Collection of platelets by automated methods, December 17, 2007. Center for Biologics Evaluation and Research, Rockville MD. Available at: file://www.fda.gov/cber/guidelines.htm (Accessed on April 02, 2009). Jilma-Stohlawetz P, Hergovich N, Homoncik M, et al. Impaired platelet function among platelet donors. Thromb Haemost 2001; 86:880. van der Linden GJ, Siegenbeek van Heukelom LH, Meinardi H. Blood donation, a risk for epileptic patients? Vox Sang 1986; 51:148. Schmidt PJ. Blood donation by the healthy elderly. Transfusion 1991; 31:681. Topic 7950 Version 13.0 © 2013 UpToDate, Inc. All rights reserved. | Subscription and License Agreement | Release: 21.6- C21.56 Licensed to: AsanBook Dig. Med. Lib. | Support Tag: [0604-125.39.66.147-4A54400AA2-S244013.14]